^
    Back
    Association details:
    Biomarker:MSH2 mutation + MSH6 mutation
    Cancer:Pituitary Gland Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Immunother Cancer
    Title:

    Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study

    Published date:
    12/22/2020
    Excerpt:
    Patient 1’s response continues 42 months after initiation of pembrolizumab and his tumor tissue obtained after treatment with temozolomide demonstrated a hypermutator phenotype with MSH2 and MSH6 gene mutations.
    DOI:
    10.1136/jitc-2020-001532